Abstract
Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATETM)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have